Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431206 | 0.83 | HSD17B10 (0.68) | HSD17B10POLBFFAR4MTNR1B | |
| SCHEMBL5743085 | 0.83 | HSD17B10 (0.68) | HSD17B10POLBFFAR4MTNR1B | |
| SCHEMBL8372012 | 0.83 | ALDH1A1 (0.44) | ALDH1A1POLBKMT2AFFAR4MTNR1B | |
| SCHEMBL6935709 | 0.81 | FFAR4 (0.46) | ALDH1A1POLBKMT2AFFAR4MTNR1B | |
| SCHEMBL8589029 | 0.81 | HSD17B10 (0.47) | HSD17B10ALDH1A1POLBKMT2APTGDR | |
| SCHEMBL16267375 | 0.81 | PTGDR (0.59) | HSD17B10ALDH1A1POLBKMT2AFFAR4 | |
| SCHEMBL20013980 | 0.78 | HSD17B10 (0.40) | HSD17B10ALDH1A1 | |
| SCHEMBL1561518 | 0.77 | FFAR4 (0.51) | HSD17B10FFAR4 | |
| SCHEMBL8619804 | 0.76 | FFAR1 (0.55) | ALDH1A1POLBFFAR4PTGDR | |
| SCHEMBL14333582 | 0.76 | CYP1A2 (0.49) | HSD17B10ALDH1A1POLBKMT2APTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | HSD17B10 1199/4885ALDH1A1 1211/4885POLB 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.